



Please use a plus sign inside this box → ☐

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB/21 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	09/830,810	
	Filing Date	October 28, 1999	
	First Named Inventor	Martin M. Matzuk	
	Group Art Unit	1653	
	Examiner Name	J. Olsen	
Total Number of Pages in This Submission	7	Attorney Docket Number	HO-P01925US1

RECEIVED

SEP 26 2002

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below)
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	Postcard
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	Copies of 25 References
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual Name	FULBRIGHT & JAWORSKI L.L.P. Melissa W. Acosta
Signature	
Date	September 23, 2002

Transmittal	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU110397828US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.	
Dated: September 23, 2002	Signature:  (Ronnie Webb)



I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EU110397828US, in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date shown below.

Dated: September 23, 2002

Signature:

*Ronnie Webb*  
(Ronnie Webb)

SEP 26 2002

TECH CENTER 1600/2900

Docket No.: HO-P01925US1  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Martin M. Matzuk, et al.

Application No.: 09/830,810

Group Art Unit: 1653

Filed: October 28, 1999

Examiner: J. Olsen

For: 311.079 OVARY-SPECIFIC GENES AND  
PROTEINS

**INFORMATION DISCLOSURE STATEMENT (IDS)**

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

Pursuant to 37 CFR 1.56, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned.

A copy of each reference on PTO/SB/08 is attached.

While the information and references disclosed in this Information Disclosure Statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. It is submitted that the Information

25211203.1

Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Commissioner is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 06-2375, under Order No. HO-P01925US1. A duplicate copy of this paper is enclosed.

Dated: September 23, 2002

Respectfully submitted,



By  
Melissa W. Acosta

Registration No.: 45,872

FULBRIGHT & JAWORSKI L.L.P.

1301 McKinney, Suite 5100

Houston, Texas 77010-3095

(713) 651-5151

(713) 651-5246 (Fax)



SEP 26 2002

TECH CENTER 1600/2900

Approved for use through 10/31/2002 OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			<b>Complete If Known</b>		
			Application Number	09/830,810	
			Filing Date	October 28, 1999	
			First Named Inventor	Martin M. Matzuk	
			Art Unit	1653	
			Examiner Name	J. Olsen	
Sheet	1	of	4	Attorney Docket Number	HO-P01925US1


U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	AA	5801016-	09-01-1998	Morioka et al.	
	AB	5547854-	08-20-1996	Donahoe et al.	
	AC	5563059-	10-08-1996	Alak et al.	
	AD	5661126-	08-26-1997	Donahoe et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	7 <sup>6</sup>
		Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)				
	BA	-WO98/40483-	09-17-1998	Human Genome Sciences, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See attached Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.



TECH CENTER 1600/2900

PTO/SB/08B (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/830,810
				Filing Date	October 28, 1999
				First Named Inventor	Martin M. Matzuk
				Group Art Unit	1653
				Examiner Name	J. Olsen
Sheet	2	of	4	Attorney Docket Number	HO-P01925US1

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA	Elvin, Julia A., et al.; Paracrine Actions of Growth Differentiatin Factor-9 in the Mammalian Ovary; Molecular Endocrinology, Vol. 13, No. 6, 1999	
	CB	Elvin, Julia A., et al.; Molecular Characterization of the Follicle Defects in the Growth Differentiation Factor 9-Deficient Ovary; Molecular Endocrinology, Vol. 13, No. 6; 1999	
	CC	Matzuk, Martin M., et al.; Transgenic Models to Study the Roles of Inhibins and Activins in Reproduction, Oncogenesis, and Development; Recent Progress in Hormone Research, Vol. 51	
	CD	Ohsumi, Keita, et al.; Characterization of the Ooplasmic Factor Inducing Decondensation of and Protamine Removal from Toad Sperm Nuclei: Involvement of Nucleoplasmin; Developmental Biology; Vol. 148; 1991	
	CE	Philpott, Anna, et al.; Nucleoplasmin Remodels Sperm Chromatin in Xenopus Egg Extracts; Cell; Vol. 69; 1992	
	CF	Matzuk, Martin M., et al.; Different phenotypes for mice deficient in either activins or activin receptor type II; Nature; Vol. 374; 1995	
	CG	Dong, Jinwen, et al.; Growth differentiation factor-9 is required during early ovarian folliculogenesis; Nature; Vol. 383; 1996	
	CH	McGrath, Sharon A., et al.; Oocyte-Specific Expression of Growth/Differentiation Factor-9; Molecular Endocrinology; Vol. 9, No. 1; 1995	
	CI	Kumar, T. Rajendra, et al.; Follicle stimulating hormone is required for ovarian follicle maturation but not male fertility; Nature Genetics; Vol. 15; 1997	
	CJ	Perreault, Sally D.; Chromatin remodeling in mammalian zygotes; Mutation Research; Vol. 296; 1992	
	CK	Krohne, Georg, et al.; Immunological identification and localization of the predominant nuclear protein of the amphibian oocyte nucleus; Proc. Natl. Acad. Sci. USA; Vol. 77; 1980	
	CL	Matzuk, Martin M. et al.; a Inhibin is a tumour-suppressor gene with gonadal specificity in mice; Nature; Vol. 360; 1992	
	CM	Elvin, Julia A., et al.; Growth differentiation factor-9 stimulates progesterone synthesis in granulosa cells via a prostaglandin E2/EP2 receptor pathway; PNAS; Vol. 97, No. 18; 2000	
	CN	MacArthur, Craig A., et al.; Npm3: A Novel, Widely Expressed Gene Encoding a Protein Related to the Molecular Chaperones Nucleoplasmin and Nucleophosmin; Genomics; Vol. 42; 1997	
	CO	Mills, A. D., et al.; An Acidic Protein Which Assembles Nucleosomes in Vitro is the Most Abundant Protein in Xenopus Oocyte Nuclei; J. Mol. Biol.; Vol. 139; 1980	
	CP	Dingwall, Colin, et al.; Nucleoplasmin cDNA sequence reveals polyglutamic acid tracts and a cluster of sequences homologous to putative nuclear localization signals; The EMBO Journal; Vol. 6, No. 1; 1987	
	CQ	McLay, David W., et al.; The Ability to Organize Sperm DNA into Functional Chromatin Is Acquired during Meiotic Maturation in Murine Oocytes; Developmental Biology; Vol. 186; 1997	
	CR	Carabatsos, Mary Jo, et al.; Characterization of Oocyte and Follicle Development in Growth Differentiation Factor-9-Devicient Mice; Developmental Biology; Vol. 204; 1998	
	CS	Philpott, Anna, et al.; Sperm Decondensatino in Xenopus Egg Cytoplasm Is Mediated by Nucleoplasmin; Cell; Vol. 65; 1991	
	CT	Burglin, Thomas R., et al.; Cloning of nucleoplasmin from Xenopus laevis oocytes and analysis of its developmental expression; Genes & Development; Vol. 1; 1987	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

25211200.1



SEP 26 2002

Approved for use through 10/31/2002 only PTO/SB/088,000-009

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<div>Substitute for form 1449B/PTO</div> <div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div>(use as many sheets as necessary)</div>				<b>Complete if Known</b>	
				Application Number	09/830,810
				Filing Date	October 28, 1999
				First Named Inventor	Martin M. Matzuk
				Group Art Unit	1653
				Examiner Name	J. Olsen
Sheet	3	of	4	Attorney Docket Number	HO-P01925US1

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.



## Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. EU110397828US in an envelope addressed to:

Commissioner for Patents  
Washington, DC 20231

on September 23, 2002  
Date

Signature

Ronnie Webb

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant